Brimonidine/ dorzolamide/ timolol - Laboratorios Sophia

Drug Profile

Brimonidine/ dorzolamide/ timolol - Laboratorios Sophia

Alternative Names: Krytantek PF; PRO-122

Latest Information Update: 29 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Laboratorios Sophia
  • Class Antiglaucomas; Antihypertensives; Eye disorder therapies; Ischaemic heart disorder therapies; Morpholines; Propanolamines; Quinoxalines; Small molecules; Sulfonamides; Thiadiazoles; Thiophenes
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Beta-adrenergic receptor antagonists; Carbonic anhydrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Ocular hypertension

Most Recent Events

  • 04 Aug 2017 Laboratorios Sophia S.A de C.V. initiates the phase III PRO-122LATAM trial in Ocular hypertension in Mexico (Ophthalmic) (NCT03193333)
  • 04 Aug 2017 Clinical trials in Ocular hypertension in Mexico (Ophthalmic)
  • 28 Jun 2017 Laboratorios Sophia plans a phase III non-inferiority trial for Ocular hypertension in patients with open-angle glaucoma (Opthalmic, preservative free solution) (NCT03193333)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top